期刊文献+

先天性神经母细胞瘤六例临床病理分析 被引量:3

Clinicopathological analysis of 6 cases of congenital neuroblastoma
下载PDF
导出
摘要 目的探讨先天性神经母细胞瘤的临床病理特征、免疫表型、分子机制、诊断及鉴别诊断。方法回顾性分析6例先天性神经母细胞瘤临床表现、病理特征、分子机制等,并随访及文献复习。结果6例病人中,囊性4例,实性2例。发病部位为肾上腺5例,后纵隔1例。镜下病理特征为肿瘤细胞被纤细纤维分割成巢团状,肿瘤细胞小而圆形,染色质细腻,可有小核仁。免疫组化PHOX2B、Syn、CgA及CD56染色均(+)。结论先天性神经母细胞瘤发病率低,生物学行为具有异质性,可自发消退或分化为良性的神经胶质瘤等,也可迅速恶化、转移迅速进展,分析其临床病理特征有助于深入了解该肿瘤的治疗与预后。 Objective To explore the clinicopathological features,immunophenotype,molecular mechanism,diagnosis and differential diagnosis of congenital neuroblastoma.Methods The clinical manifestations,pathological features,and molecular mechanisms of 6 cases of congenital neuroblastoma were retrospectively analyzed,followed by telephone follow-up and literature review.Results Among the 6 patients,4 were cystic and 2 were solid.Five cases were adrenal glands and one case was posterior mediastinum.The pathological feature under the microscope is that the tumor cells are divided into nests by fine fibers,the tumor cells are small and round,the chromatin is fine,and there may be small nucleoli.Immunohistochemistry showed PHOX2 B,Syn,CgA and CD56 were all positive.Conclusion The incidence of congenital neuroblastoma is low,and the biological behavior is heterogeneous.It can regress spontaneously or differentiate into a benign glioma.It can also rapidly deteriorate and metastasize rapidly.Analysis of its clinicopathological features helps In-depth understanding of the treatment and prognosis of this tumor.
作者 张艳丽 胡俊波 郭鹏 刘涵瀚 ZHANG Yanli;HU Junbo;GUO Peng(Department of Pathology,Hubei Maternal and Child Health Hospital,Hubei,Wuhan 430070,China)
出处 《临床外科杂志》 2021年第9期880-882,共3页 Journal of Clinical Surgery
关键词 先天性神经母细胞瘤 囊性 肾上腺 PHOX2B congenital neuroblastoma cystic adrenal PHOX2B
  • 相关文献

参考文献2

二级参考文献18

  • 1Howlader N, Noone AM, Krapcho M, et al, eds. SEER statistics review, 1975-2009 ( Vintage 2009 Populations)[M]. Bethesda, Md: National Cancer Institute, 2012.
  • 2Homer M J, Ries LA, Krapcho M, et al. SEER cancer statistics review, 1975-2006[M]. Bethesda, Md: National Cancer Institute, 2009.
  • 3Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, andresponse to treatment[J]. J Clin Oncol, 1993, 11 (8): 1466- 1477.
  • 4Shimada H,Ambros IM, Dehner LP, et al. The Ivtemational Neuroblastoma Pathology Classification (the Shimada system) [J]. Cancer,1999,86 (2) : 364-372.
  • 5Peuchmaur M Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular [J ]. Cancer, 2003, 98 (10) : 2274-2281.
  • 6Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report [J]. J Clin Oncol , 2009, 27 (2): 298-303.
  • 7Brisse HJ,McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project[D]. Radiology, 2011, 261 (1) : 243-257.
  • 8Brodeur GM,Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[J]. J Clin Oncol, 1993,11 (8) : 1466- 1477.
  • 9Strother DR,London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641[J]. J Clin Oncol , 2012, 30 (15) : 1842-1848.
  • 10Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma[J]. N Engl J Med, 2010,363 (14): 1313-1323.

共引文献92

同被引文献26

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部